News Conference News ESC 2022 INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF Michael O'Riordan August 28, 2022
News Conference News ESC 2020 VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban L.A. McKeown September 03, 2020
News Conference News ESC 2019 Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints Todd Neale September 11, 2019
News Conference News ESC 2019 LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17 Todd Neale September 10, 2019
News Conference News ESC 2019 For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI Todd Neale September 03, 2019
News Conference News ESC 2019 AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD Todd Neale September 02, 2019
News Conference News ESC 2019 ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More Shelley Wood August 22, 2019
News Conference News ESC 2018 COMMANDER HF: Low-Dose Rivaroxaban Flops in Heart Failure Todd Neale August 27, 2018
News Conference News ESC 2018 MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis Todd Neale August 26, 2018
News Conference News ESC 2018 ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More Shelley Wood August 20, 2018
News Opinion Editor's Corner ESC 2017 My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back Shelley Wood September 08, 2017
News Conference News ESC 2017 EMANATE: Another NOAC Shown to Be Safe, Effective in the Setting of Cardioversion for A-fib Todd Neale September 05, 2017
News Conference News ESC 2017 COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease Todd Neale August 27, 2017
News Opinion Editor's Corner ESC 2017 ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On Shelley Wood August 18, 2017
News Conference News ESC 2016 Reversal Agent for Factor Xa Inhibitors Rapidly Reduces Anticoagulant Effects: ANNEXA-4 Todd Neale August 31, 2016
News Conference News ESC 2016 NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry Michael O'Riordan August 28, 2016
News Conference News ESC 2012 Low-Dose Rivaroxaban Curbs Thrombotic Events in STEMI Patients Caitlin E. Cox August 27, 2012